Početna stranicaGIFOF • OTCMKTS
add
Grifols SA Preference Shares Class B
Preth. zaklj. cijena
7,42 $
Godišnji raspon
5,58 $ - 9,40 $
Tržišna kapitalizacija
5,97 mlr. USD
Prosječna količina
10,00
P/E omjer
-
Prinos dividende
-
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(EUR) | ruj 2024.info | Godišnja promjena |
---|---|---|
Prihod | 1,79 mlr. | 12,24 % |
Operativni troškovi | 376,78 mil. | −3,08 % |
Neto dohodak | 51,69 mil. | −13,19 % |
Neto profitabilnost | 2,88 | −22,79 % |
Zarada po dionici | — | — |
EBITDA | 468,09 mil. | 33,73 % |
Efektivna porezna stopa | 31,35 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(EUR) | ruj 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 806,74 mil. | 66,60 % |
Ukupna imovina | 20,28 mlr. | −8,07 % |
Ukupne obveze | 12,29 mlr. | −8,95 % |
Ukupni kapital | 8,00 mlr. | — |
Dionice u optjecaju | 679,63 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,94 | — |
Povrat imovine | 4,22 % | — |
Povrat kapitala | 4,78 % | — |
Tok novca
Neto promjena novca
(EUR) | ruj 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | 51,69 mil. | −13,19 % |
Gotovina od poslovanja | 299,61 mil. | 92,51 % |
Gotovina iz ulaganja | −196,40 mil. | −59,83 % |
Gotovina iz financiranja | −1,56 mlr. | −1.860,81 % |
Neto promjena novca | −1,47 mlr. | −3.652,69 % |
Slobodan tok novca | 243,60 mil. | 627,76 % |
Više
Grifols, S.A. is a global healthcare company and manufacturer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,000employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceutical solutions, the company is also a leader in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Its portfolio of solutions is designed to enhance safety from donation to transfusion. Grifols also provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. Additionally, the company supply tools, information and services that enable hospitals, pharmacies and healthcare professionals to deliver expert medical care. Wikipedia
Glavni izvršni direktor
Osnovano
18. stu 1940.
Web-lokacija
Zaposlenici
23.000